Drugs / OT-82
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03921879 | Jul 2019 → Apr 2021 | Hodgkins lymphoma, T-cell non-Hodgkin lymphoma, follicular lymphoma, peripheral T-cell lymphoma, not otherwise specified | Oncotartis, Inc. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OT-82 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03921879 ↗ |
| Route | Oral | “given orally as an oral suspension” NCT03921879 ↗ |